阿瑞匹坦联合昂丹司琼和地塞米松预防化疗诱发恶心和呕吐的疗效及安全性

doi:10.3760/cma.j.issn.1673422X.2016.08.001

摘要/Abstract

摘要： 目的评估阿瑞匹坦联合昂丹司琼和地塞米松预防化疗诱发恶心和呕吐(CINV)的疗效及安全性。方法本研究是前瞻性非随机、自身对照的单中心研究，入组43例接受中、高度致吐风险化疗的患者。所有患者在化疗前使用阿瑞匹坦(125 mg第1天，80 mg第2～3天)联合昂丹司琼(16 mg第1～3天)和地塞米松(10 mg第1～3天)进行预防止吐治疗（阿瑞匹坦组）。同一患者使用相同剂量的昂丹司琼联合地塞米松（自身对照组）作自身前后对照。主要研究终点为化疗后120 h内完全有效率(没有呕吐和没有使用解救治疗患者比例)。根据美国国立癌症研究所的通用毒性标准(NCICTC 4.0)评估不良反应。结果阿瑞匹坦组总体完全有效率为72.1%(31/43)，优于自身对照组51.2%(22/43，χ²=3.98，P＜0.05)。对于急性期呕吐(化疗后＜24 h)，阿瑞匹坦组完全有效率为83.7%(36/43)，对照组为74.4%(32/43，χ²=1.12，P＞0.05)。对于延迟期呕吐，两组完全有效率分别为76.7%(33/43)和55.8%(24/43，χ²=4.21，P＜0.05)。两种止吐方案毒性和不良事件相似.结论阿瑞匹坦联合昂丹司琼和地塞米松方案能够有效预防中、高度致吐化疗药物引起的恶心和呕吐，且安全性良好。

关键词: 恶心, 呕吐, 抗肿瘤联合化疗方案, 治疗效果, 阿瑞匹坦

Abstract: Objective To evaluate the efficacy and safety of the new combination (aprepitant/ondansetron/dexamethasone) in the prevention of chemotherapyinduced nausea and vomiting (CINV). Methods This was a prospective nonrandomized, selfcontrol single site study, and 43 patients receiving high and moderate emetic risk chemotherapy were enrolled. All patients received the following regimen for the prevention of CINV (day 1, 125 mg aprepitant, 16 mg ondansetron, and 10 mg dexamethasone before chemotherapy; and days 23, 80 mg aprepitant, 16 mg ondansetron, and 10 mg dexamethasone each day). The same dose of ondansetron and dexamethasone was used as selfcontrol in the previous or next course of the chemotherapy in the same patient. The primary end point was the proportion of patients with complete response (no emesis and no rescue therapy) during the 120 h postchemotherapy. Toxicity assessments were conducted using the NCICTC investigator guide (version 4.0). Results The overall complete response (CR) rates were 72.1% in the aprepitant group (31/43) versus 51.2% in the selfcontrol group (22/43; χ²=3.98, P＜0.05). For the acute phase (＜24 h postchemotherapy), the CR rates were 83.7% (36/43) in the aprepitant group and 74.4% (32/43) in the selfcontrol group (χ²=1.12, P＞0.05). For the delayed phase, the CR rates were 76.7% (33/43) and 55.8% (24/43), respectively (χ²=4.21, P＜0.05). Toxicity and adverse events were comparable in both groups. Conclusion The combination of aprepitant, ondansetron and dexamethasone is effective and well tolerable for CINV prevention in cancer patients receiving high and moderate emetic risk chemotherapy.

Key words: Nausea, Vomiting, Antineoplastic combined chemotherapy protocols, Treatment outcome, Aprepitant

李开春, 王静文, 施展, 庄杰, 陈玺, 陈佳艳, 唐曦, 李进. 阿瑞匹坦联合昂丹司琼和地塞米松预防化疗诱发恶心和呕吐的疗效及安全性[J]. 国际肿瘤学杂志, 2016, 43(8): 561-564.

Li Kaichun, Wang Jingwen, Shi Zhan, Zhuang Jie, Chen Xi, Chen Jiayan, Tang Xi, Li Jin. Efficacy and safety of aprepitant combined with ondansetron and dexamethasone in the prevention of chemotherapyinduced nausea and vomiting[J]. Journal of International Oncology, 2016, 43(8): 561-564.

参考文献

［1］ Ettinger DS, Armstrong DK, Barbour S, et al. Antiemesis［J］. J Natl Compr Canc Netw, 2012, 10(4): 456-485. ［2］ Jordan K, Gralla R, Jahn F, et al. International antiemetic guidelines on chemotherapy induced nausea and vomiting (CINV): content and implementation in daily routine practice［J］. Eur J Pharmacol, 2014, 722: 197-202. DOI: 10.1016/j.ejphar.2013.09.073. ［3］ Molassiotis A, Nguyen AM, Rittenberg CN, et al. Analysis of aprepitant for prevention of chemotherapyinduced nausea and vomiting with moderately and highly emetogenic chemotherapy［J］. Future Oncol, 2013, 9(10): 1443-1450. DOI: 10.2217/fon.13.155. ［4］ HuynhLe MP, Zhang Z, Tran PT, et al. Low interrater reliability in grading of rectal bleeding using National Cancer Institute Common Toxicity Criteria and Radiation Therapy Oncology Group Toxicity scales: a survey of radiation oncologists［J］. Int J Radiat Oncol Biol Phys, 2014, 90(5): 1076-1082. DOI: 10.1016/j.ijrobp.2014.08.014. ［5］ Jordan K, Jahn F, Aapro M. Recent developments in the prevention of chemotherapyinduced nausea and vomiting (CINV): a comprehensive review［J］. Ann Oncol, 2015, 26(6): 1081-1090. DOI: 10.1093/annonc/mdv138. ［6］ Aapro M, Carides A, Rapoport BL, et al. Aprepitant and fosaprepitant: a 10year review of efficacy and safety［J］. Oncologist, 2015, 20(4): 450458. DOI: 10.1634/theoncologist.2014-0229. ［7］ Rojas C, Raje M, Tsukamoto T, et al. Molecular mechanisms of 5-HT(3) and NK(1) receptor antagonists in prevention of emesis［J］. Eur J Pharmacol, 2014, 722: 26-37. DOI: 10.1016/j.ejphar.2013.08.049. ［8］ Hesketh PJ, Grunberg SM, Gralla RJ, et al. The oral neurokinin1 antagonist aprepitant for the prevention of chemotherapyinduced nausea and vomiting: a multinational, randomized, doubleblind, placebocontrolled trial in patients receiving highdose cisplatinthe Aprepitant Protocol 052 Study Gr［J］. J Clin Oncol, 2003, 21(22): 4112-4119. DOI: 10.1200/JCO.2003.01.095. ［9］ PoliBigelli S, RodriguesPereira J, Carides AD, et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapyinduced nausea and vomiting. Results from a randomized, doubleblind, placebocontrolled trial in Latin America［J］. Cancer, 2003, 97(12): 3090-3098. DOI: 10.1002/cncr.11433. ［10］ Morrow GR, Navari RM, Rugo HS. Clinical roundtable monograph: new data in emerging treatment options for chemotherapyinduced nausea and vomiting［J］. Clin Adv Hematol Oncol, 2014, 12(3 Suppl 9): 1-14; quiz 15. ［11］ Warr DG, Grunberg SM, Gralla RJ, et al. The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapyinduced nausea and vomiting: pooled data from 2 randomised, doubleblind, placebo controlled trials［J］. Eur J Cancer, 2005, 41(9): 1278-1285. DOI: 10.1016/j.ejca.2005.01.024. ［12］ Hu Z, Cheng Y, Zhang H, et al. Aprepitant triple therapy for the prevention of chemotherapyinduced nausea and vomiting following highdose cisplatin in Chinese patients: a randomized, doubleblind, placebocontrolled phase Ⅲ trial［J］. Support Care Cancer, 2014, 22(4): 979-987. DOI: 10.1007/s00520-013-2043-9. ［13］ Wang SY, Yang ZJ, Zhang Z, et al. Aprepitant in the prevention of vomiting induced by moderately and highly emetogenic chemotherapy［J］. Asian Pac J Cancer Prev, 2014, 15(23): 10045-10051. ［14］ Hu W, Fang J, Nie J, et al. Addition of aprepitant improves protection against cisplatininduced emesis when a conventional antiemetic regimen fails［J］. Cancer Chemother Pharmacol, 2014, 73(6): 1129-1136. DOI: 10.1007/s00280-014-2446-4.

[1]	姜溪, 武永存, 梁艳, 楚丽, 段颖欣, 王力军, 霍俊杰. 派安普利单抗联合化疗对晚期非小细胞肺癌患者血管生成及循环内皮细胞的影响[J]. 国际肿瘤学杂志, 2024, 51(2): 89-94.
[2]	安荣, 刘美华, 王佩晨, 王晓慧. Nrf2在卵巢癌中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(8): 493-497.
[3]	林榕生, 吴楚海, 郭颖梅, 王涛, 陈荣斌, 刘少琴, 甘兵. 特瑞普利单抗联合贝伐珠单抗二线以上治疗MSI-H型转移性结直肠癌的疗效及安全性[J]. 国际肿瘤学杂志, 2022, 49(2): 100-105.
[4]	侯莉娜, 迪娜·索力提肯, 郭智, 陈晓, 任骅. PD-1抑制剂单药治疗与联合化疗/靶向治疗晚期恶性肿瘤的疗效及安全性比较[J]. 国际肿瘤学杂志, 2020, 47(4): 193-198.
[5]	沈夏波, 王伟, 潘跃银. 血细胞参数在小细胞肺癌治疗中的预测作用[J]. 国际肿瘤学杂志, 2019, 46(8): 496-499.
[6]	张羽，徐滨，王冬梅. 3DCRT联合沙利度胺、GEMOX方案化疗对晚期肝内胆管细胞癌的疗效分析[J]. 国际肿瘤学杂志, 2019, 46(5): 262-266.
[7]	衣明慧，李振江，曹强，李宝生. CT纹理分析预测食管鳞状细胞癌放化疗敏感性的研究[J]. 国际肿瘤学杂志, 2019, 46(3): 141-146.
[8]	李喆，邢言珂，李宝生. 原发性食管小细胞癌不同临床特征及治疗方案的疗效分析[J]. 国际肿瘤学杂志, 2019, 46(3): 129-134.
[9]	田梦, 李振祥, 付成瑞, 李宝生, 孙新臣. 血清低密度脂蛋白在广泛期小细胞肺癌一线治疗中的预测价值[J]. 国际肿瘤学杂志, 2019, 46(12): 734-740.
[10]	张宝玉, 王铁君. 外阴癌放射治疗进展[J]. 国际肿瘤学杂志, 2019, 46(11): 699-704.
[11]	郑林晶，董银萍，胡兵，夏重升，李宝生，黄伟. 乳腺癌保乳术后大分割放疗的研究进展[J]. 国际肿瘤学杂志, 2018, 45(8): 570-573.
[12]	王刚,王黄震,薛挺. 奥沙利铂诱导的细胞自噬对胃癌SGC7901细胞耐药的影响[J]. 国际肿瘤学杂志, 2018, 45(8): 513-518.
[13]	王大中. 铂类为基础的双药二线治疗方案对NSCLC患者预后的影响及其相关因素分析[J]. 国际肿瘤学杂志, 2018, 45(5): 269-272.
[14]	高海燕,朱玉兰,孙立. 化疗联合DC-CIK细胞免疫治疗在转移性乳腺癌中的疗效观察[J]. 国际肿瘤学杂志, 2016, 43(5): 326-329.
[15]	汪旭, 佟仲生, 陈建华, 庄志祥, 陈德玉, 张西志, 童建东, 吴昌平, 于浩,李淑芬,史业辉. 帕洛诺司琼注射液预防化疗引起呕吐的疗效观察[J]. 国际肿瘤学杂志, 2016, 43(1): 12-16.